|
Market Closed -
NYSE
21:00:02 11/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 48.13 USD | +0.02% |
|
-3.53% | -1.86% |
| 09-11 | GSK to shut vaccine factory in Germany, putting 641 jobs at risk | RE |
| 09-10 | GSK gets Japan approval for prefilled Shingrix vaccine | AN |
| Market Cap | 70.94B 95.9B 82.66B 78.27B 133B 9,165B 134B 931B 358B 4,660B 360B 352B 14,740B | P/E 2026 * |
13.5x | P/E 2027 * | 11.1x |
|---|---|---|---|---|---|
| Enterprise Value | 91.67B 124B 107B 101B 172B 11,842B 173B 1,202B 462B 6,021B 465B 455B 19,045B | EV / Sales 2026 * |
2.7x | EV / Sales 2027 * | 2.51x |
| Free-Float |
92.75% | Yield 2026 * |
3.93% | Yield 2027 * | 4.23% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Tradegate
| GS70 | Real-time | |
|
Mexican S.E.
| GSK N | End-of-day quote | |
|
Deutsche Boerse AG
| GS70 | Delayed | |
|
Börse Stuttgart
| GS70 | Delayed | |
|
Boerse Muenchen
| GS70 | Real-time |
Last Transcript : GSK plc
| 1 day | +0.02% | ||
| 1 week | -3.53% | ||
| Current month | -4.22% | ||
| 1 month | -5.44% | ||
| 3 months | -8.95% | ||
| 6 months | -12.73% | ||
| Current year | -1.86% |
| 1 week | 47.85 |  | 49.23 |
| 1 month | 47.85 | | 52.94 |
| Current year | 47.62 | | 61.7 |
| 1 year | 39.29 | | 61.7 |
| 3 years | 31.72 | | 61.7 |
| 5 years | 28.46 | | 61.7 |
| 10 years | 28.46 | | 61.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 31/12/2025 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 30/04/2023 |
James Ford
CMP | Compliance Officer | - | 31/07/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 05/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 31/12/2017 |
Jonathan Symonds
CHM | Chairman | 67 | 31/08/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.02% | -3.53% | - | - | 95.94B | |
| -0.65% | -2.93% | +47.52% | +87.34% | 994B | |
| -0.29% | -3.51% | +48.78% | +63.27% | 640B | |
| +0.83% | +0.26% | +16.76% | +72.52% | 454B | |
| -0.38% | -3.59% | +28.24% | +35.57% | 337B | |
| -0.09% | -13.54% | +10.08% | +26.87% | 261B | |
| -0.43% | -2.48% | -2.07% | +11.48% | 246B | |
| -1.34% | -13.70% | +33.47% | +44.18% | 204B | |
| -3.44% | -7.51% | -20.08% | -59.58% | 190B | |
| -0.75% | -4.82% | +21.94% | +86.55% | 178B | |
| Average | -0.65% | -5.76% | +20.52% | +40.91% | 389.42B | |
| Weighted average by Cap. | -0.49% | -4.42% | +29.87% | +55.71% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.95B 45.89B 39.55B 37.45B 63.66B 4,386B 64.01B 445B 171B 2,230B 172B 169B 7,054B | 35.49B 47.98B 41.35B 39.15B 66.55B 4,585B 66.92B 466B 179B 2,331B 180B 176B 7,374B |
| Net income | 5.38B 7.27B 6.27B 5.94B 10.09B 695B 10.14B 70.58B 27.12B 353B 27.31B 26.71B 1,118B | 6.37B 8.62B 7.43B 7.03B 11.95B 823B 12.02B 83.62B 32.13B 419B 32.35B 31.64B 1,324B |
| Net Debt | 20.72B 28.01B 24.14B 22.86B 38.86B 2,677B 39.07B 272B 104B 1,361B 105B 103B 4,305B | 17.98B 24.31B 20.95B 19.84B 33.72B 2,323B 33.91B 236B 90.65B 1,181B 91.29B 89.29B 3,737B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/09/26 | US$48.13 | +0.02% | 2,276,994 |
| 10/09/26 | US$48.12 | -1.05% | 2,151,048 |
| 09/09/26 | US$48.63 | +0.19% | 2,405,273 |
| 08/09/26 | US$48.54 | -2.71% | 3,062,276 |
| 04/09/26 | US$49.89 | -1.93% | 2,287,091 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
